Bictegravir/Emtricitabine/Tenofovir Alafenamide Dosing
The standard dose of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is one 50/200/25 mg tablet taken orally once daily with or without food for HIV treatment in adults and adolescents weighing ≥25 kg 1.
Standard Dosing for HIV Treatment
- Adults and adolescents ≥25 kg: One tablet of 50 mg bictegravir/200 mg emtricitabine/25 mg tenofovir alafenamide once daily 1
- Pediatric patients 14 to <25 kg: One tablet of 30 mg bictegravir/120 mg emtricitabine/15 mg tenofovir alafenamide once daily 1
- Can be taken with or without food 1
B/F/TAF is recommended as a first-line regimen for most people with HIV, with strong evidence supporting its use (evidence rating: AIa) 2.
Renal Impairment Adjustments
No dose adjustment is required for creatinine clearance (CrCl) ≥30 mL/min 1. This represents a significant advantage over many other regimens, as B/F/TAF is the first non-boosted integrase inhibitor-based single-tablet regimen suitable for patients with moderate renal impairment.
Specific Renal Dosing Guidelines:
- CrCl ≥30 mL/min: Standard dose, no adjustment needed 1
- CrCl 15-29 mL/min: Not recommended unless patient is virologically suppressed and on chronic hemodialysis 1
- End-stage renal disease (ESKD) on chronic hemodialysis: Standard dose can be used in virologically suppressed patients; administer after hemodialysis on dialysis days 1, 3
- ESKD not on dialysis or treatment-naive patients on dialysis: Not recommended due to lack of safety and efficacy data 1
Recent evidence demonstrates that B/F/TAF maintains virological suppression effectively in patients with ESKD on hemodialysis, with bictegravir trough concentrations remaining 4-7 fold above the therapeutic threshold despite being lower than in patients with normal renal function 3.
Pregnancy Dosing
B/F/TAF can be used during pregnancy at the standard dose (50/200/25 mg once daily), though it is not the preferred first-line option 2.
Pregnancy-Specific Considerations:
- Preferred regimen in pregnancy: Tenofovir alafenamide/emtricitabine (or lamivudine) plus dolutegravir (evidence rating: AIa) 2
- B/F/TAF as alternative: Acceptable option (evidence rating: BIIb) 2
- If already on B/F/TAF when pregnancy diagnosed: Continue the regimen if tolerated and effective (evidence rating: AIIa) 2
- Standard dose maintained: No dose adjustment needed during pregnancy 4, 5
Critical caveat: Bictegravir exposure decreases significantly during pregnancy—area under the curve is 46% lower in second trimester and 52% lower in third trimester compared to postpartum 4. However, trough concentrations remain above the therapeutic threshold (protein-adjusted 95% effective concentration of 0.162 μg/mL) 4. Despite lower exposure, 88-92% of participants maintained viral suppression <40 copies/mL throughout pregnancy 4.
Adherence is absolutely critical during pregnancy: Missing even a single dose during the third trimester results in 43.7% of patients falling below therapeutic concentrations, and two consecutive missed doses result in 90.4% below target 5. This makes adherence counseling paramount when using B/F/TAF in pregnancy.
Post-Exposure Prophylaxis (PEP)
B/F/TAF can be used for post-exposure prophylaxis at the standard dose of one 50/200/25 mg tablet once daily for 28 days 6.
- Demonstrated excellent tolerability with 90.4% completion rate 6
- Lower side effect profile compared to historical PEP regimens 6
- Most common side effects: nausea/vomiting (15.4%), fatigue (9.6%), diarrhea (7.7%) 6
- All participants who completed the regimen remained HIV-negative 6
While not explicitly mentioned in the 2024 IAS-USA guidelines for PEP, the favorable safety profile and once-daily single-tablet formulation make it a practical option.
Hepatic Impairment
- Mild to moderate hepatic impairment (Child-Pugh A or B): No dose adjustment needed 1
- Severe hepatic impairment (Child-Pugh C): Not recommended—has not been studied in this population 1
Special Populations Requiring Caution
Do not use B/F/TAF in the following scenarios without resistance testing results:
- Patients who acquired HIV while on tenofovir alafenamide/emtricitabine or tenofovir disoproxil fumarate/emtricitabine for PrEP: Start a 3-drug regimen (preferably dolutegravir or bictegravir plus nucleoside backbone) but obtain genotyping first 2
- Patients with prior cabotegravir exposure for PrEP: Obtain integrase inhibitor genotyping before starting; if resistance suspected, use boosted darunavir-based regimen instead 2
Key Clinical Advantages
B/F/TAF offers several practical benefits:
- Single-tablet, once-daily regimen improves adherence
- No food requirements
- No HLA-B*5701 testing needed (unlike abacavir-containing regimens), enabling rapid treatment initiation
- Active against hepatitis B (contains tenofovir alafenamide and emtricitabine) 7
- Usable in moderate renal impairment (CrCl ≥30 mL/min) without dose adjustment
- High genetic barrier to resistance—no resistance emergence reported in phase 3 trials 7